AC Immune SA
ACIU
$2.19
$0.041.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 43.77% | -14.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 43.77% | -14.95% | |||
| Cost of Revenue | 15.21% | -1.50% | |||
| Gross Profit | -13.32% | 0.46% | |||
| SG&A Expenses | -4.44% | 8.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -3,181.82% | 106.92% | |||
| Total Operating Expenses | 10.77% | 0.68% | |||
| Operating Income | -9.08% | -1.63% | |||
| Income Before Tax | -21.35% | -17.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.35% | -17.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.35% | -17.67% | |||
| EBIT | -9.08% | -1.63% | |||
| EBITDA | -9.07% | -1.70% | |||
| EPS Basic | -21.11% | -17.18% | |||
| Normalized Basic EPS | -21.02% | -17.26% | |||
| EPS Diluted | -21.11% | -15.25% | |||
| Normalized Diluted EPS | -21.02% | -17.26% | |||
| Average Basic Shares Outstanding | 0.22% | 0.42% | |||
| Average Diluted Shares Outstanding | 0.22% | 0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||